logo-loader
NASDAQ:OTLK

Outlook Therapeutics Inc

Receive alerts
Market:
NASDAQ
Price
9.37 USD
Day Change
7.95%
Market Cap:
$202.24 m
52 weeks high
40.40
52 weeks low
4.01

In brief

Outlook Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications. Its goal is to launch ONS-5010 as the first, and only, approved bevacizumab in the United States, Europe, Japan and other markets for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).